An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study by Proctor, M J et al.
An inflammation-based prognostic score (mGPS) predicts
cancer survival independent of tumour site: a Glasgow
Inflammation Outcome Study
MJ Proctor*,1, DS Morrison
2, D Talwar
3, SM Balmer
3, DSJ O’Reilly
3, AK Foulis
4, PG Horgan
1 and DC McMillan
1
1University Department of Surgery, Faculty of Medicine-University of Glasgow, Royal Infirmary, Glasgow G31 2ER, UK;
2West of Scotland Cancer
Surveillance Unit, Faculty of Medicine-University of Glasgow, Glasgow G12 8RZ, UK;
3Department of Clinical Biochemistry, Royal Infirmary, Glasgow G31
2ER, UK;
4Department of Clinical Pathology, Royal Infirmary, Glasgow G31 2ER, UK
INTRODUCTION: A selective combination of C-reactive protein and albumin (termed the modified Glasgow Prognostic Score, mGPS)
has been shown to have prognostic value, independent of tumour stage, in lung, gastrointestinal and renal cancers. It is also
of interest that liver function tests such as bilirubin, alkaline phosphatase and g-glutamyl transferase, as well as serum calcium, have
also been reported to predict cancer survival. The aim of the present study was to examine the relationship between an
inflammation-based prognostic score (mGPS), biochemical parameters, tumour site and survival in a large cohort of patients with
cancer.
METHODS: Patients (n¼21669) who had an incidental blood sample taken between 2000 and 2006 for C-reactive protein, albumin
and calcium (and liver function tests where available) and a diagnosis of cancer were identified. Of this group 9608 patients who had
an ongoing malignant process were studied (sampled within 2 years before diagnosis). Also a subgroup of 5397 sampled at the time
of diagnosis (sampled within 2 months prior to diagnosis) were examined. Cancers were grouped by tumour site in accordance
with International Classification of Diseases 10 (ICD 10).
RESULTS: On follow up, there were 6005 (63%) deaths of which 5122 (53%) were cancer deaths. The median time from blood
sampling to diagnosis was 1.4 months. Increasing age, male gender and increasing deprivation was associated with a reduced 5-year
overall and cancer-specific survival (all Po0.001). An elevated mGPS, adjusted calcium, bilirubin, alkaline phosphatase, aspartate
transaminase, alanine transaminase and g-glutamyl transferase were associated with a reduced 5-year overall and cancer-specific
survival (independent of age, sex and deprivation in all patients sampled), as well as within the time of diagnosis subgroup
(all Po0.001). An increasing mGPS was predictive of a reduced cancer-specific survival in all cancers (all Po0.001).
CONCLUSION: The results of the present study indicate that the mGPS is a powerful prognostic factor when compared with other
biochemical parameters and independent of tumour site in patients with cancer.
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Cancer incidence is increasing in the United Kingdom as well as on
a global basis (Boyle and Levin, 2008). Over one in three people in
the United Kingdom will develop cancer during their lifetime, with
around 150000 people dying each year as a consequence of cancer
(Cancer Research UK, 2007, 2008). Such a burden of disease
accounts for a significant proportion of annual health care
spending in the United Kingdom, United States and worldwide
(Bosanquet and Sikora, 2004; Boyle and Levin, 2008).
Although it is recognised that the development of cancer has a
genetic basis, there is increasing evidence that the host inflamma-
tory response has an important role in the development and
progression of cancer (Coussens and Werb, 2002; Mantovani et al,
2008; Colotta et al, 2009; McDonald et al, 2009; Tenesa et al, 2010).
In particular the systemic inflammatory response, as evidence by
C-reactive protein, has an important role in the progression of a
variety of common solid tumours (Roxburgh and McMillan, 2010).
The measurement of the systemic inflammatory response
has been subsequently refined using a selective combination of
C-reactive protein and albumin (termed the modified Glasgow
Prognostic Score, mGPS) and has been shown to have prognostic
value, independent of tumour stage, in lung, gastrointestinal and
renal cancers (McMillan, 2008, 2009). It is also of interest that liver
function tests such as bilirubin (Temme et al, 2001), alkaline
phosphatase (Tonelli et al, 2009) and g-glutamyl transferase
(Kazemi-Shirazi et al, 2007) as well as serum calcium (Leifsson
and Ahren, 1996), have also been reported to predict cancer and
non-cancer mortality in large cohort studies.
More recently it has been shown that, in a large cohort study
of 4200000 patients (Glasgow Inflammation Outcome Study)
that the mGPS is elevated in patients with cancer when compared
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swith those without cancer. Moreover, that there were significant
inter-relationships between the above biochemical parameters,
including those used to compose the mGPS (Proctor et al, 2010).
Together with these results, the question is therefore raised
whether the mGPS and other routine biochemical parameters have
independent prognostic value in patients with cancer and whether
this applies across different tumour sites.
The aim of the present study was to examine the relationship
between an inflammation-based prognostic score (mGPS),
biochemical parameters, tumour site and survival in patients with
cancer of the Glasgow Inflammation Outcome Study.
MATERIALS AND METHODS
Study design
From a cohort previously described (Proctor et al, 2010), patients
in the North Glasgow who had a single blood sample taken for
C-reactive protein, albumin and calcium, as well as liver function
tests where available, and a diagnosis of cancer were considered.
Briefly, patients who were sampled incidentally between the 1
January 2000 and the 31 December 2006 were considered and if
more than one set of measurements were available for a given
patient, only the initial set was used. Only patients with blood
samples taken within two years prior to their cancer diagnosis
were included. This was done with the premise that they would
likely have an ongoing malignant process at the time of sampling.
Also, only patients who had complete Cancer Registry follow up
(detailed below) were included in the study. Patients were excluded
if they were under 16 or did not have a complete set of identifying
details (name, date of birth and hospital number).
Cancer diagnosis was established through linkage with the
Scottish Cancer Registry using exact matches of patients’ fore-
name, surname and date of birth followed by a Soundex phonetic
matching algorithm if initial exact matching was unsuccessful. At
the time of data collection, the Scottish Cancer Registry held
complete pathological and clinical cancer diagnosis records from
1 January 1980 to 31 December 2006 and mortality follow-up until
30 June 2009. In those who had died, cancer-specific deaths were
classified as patients whose primary cause of death matched their
primary cancer diagnosis. All other deaths were classed as non-
cancer-specific deaths.
Cancers were coded in accordance with the International Classi-
fication of Disease 10 (ICD 10) and broadly grouped according to
tumour sites: breast, bladder, gynaecological, prostate, gastro-
esophageal, haematological, renal, colorectal, head and neck,
hepatopancreaticobiliary and pulmonary cancer. These groups
were listed in order of the magnitude of their inflammatory status
as shown previously (Proctor et al, 2010). Patients with multiple
malignancies, metastatic disease or cancer of an unknown origin
were excluded.
The study was approved by the Research Ethics Committee,
North Glasgow NHS Trust.
Methods
Patients with routine laboratory measurements of C-reactive
protein, albumin and calcium were obtained by systematically
searching the North Glasgow biochemical database system. The
limit of detection of C-reactive protein was a concentration of
o5mgl
 1. The mGPS was constructed, using C-reactive protein
and albumin, as follows: patients with both an elevated C-reactive
protein (X10mgl
 1) and low albumin (o35gl
 1) were allocated a
score of 2; patients in whom only C-reactive protein was elevated
(X10mgl
 1) were allocated a score of 1 and those with a normal
C-reactive protein were allocated a score of 0 (McMillan et al,
2007). The rationale and basis of the mGPS has been previously
described (McMillan et al, 2008). Serum C-reactive protein,
albumin and liver function tests, including bilirubin, Alk phos,
AST, ALT and GGT, as well as calcium adjusted for albumin
(Ashby et al, 1986), were classified in accordance with the NHS
Greater Glasgow and Clyde Biochemistry Laboratory reference
ranges.
ICD 10 codes were used to identify the site of cancer diagnosis.
These include breast (C50), bladder (C67), gynaecological
(C51–58), prostate (C61), gastroesophageal (C15–16), haematolo-
gical (C81–96), renal (C64–65), colorectal (C18–20), head and
neck (C00–14, C30–32), hepatopancreaticobiliary (C22–25) and
pulmonary (C34, C45) cancer.
Deprivation was measured with the Scottish Index of Multiple
Deprivation (SIMD) 2006 and in this study was presented with the
least deprived being scored as 1 to the most deprived scoring 5.
The SIMD 2006 classification of deprivation is based on an
individual’s postcode and is derived from the measurements of 37
indicators across seven domains including income, employment,
education, housing, health, crime and geographical access. The
SIMD 2006 is the recommended method for the measurement of
deprivation in Scotland by the Information Services Division on
behalf of NHS Scotland and the Scottish Government Department
of Health (Bishop et al, 2004).
Statistical analysis
Survival, overall and cancer-specific, was calculated from the time
of cancer diagnosis to death. Cancer groups with o150 cancer-
specific deaths were excluded to ensure the statistical power.
Analysis was carried on all cancer patients as well as on a subgroup
of patients who had a diagnosis of cancer made within 2 months
following their blood sample. This was carried out in order to
examine the relationships between the mGPS, biochemical
parameters and survival in all patients with a likely ongoing
malignant process (patients sampled within 2 years before a
diagnosis of cancer) and those at the time of diagnosis (patients
sampled within 2 months before a diagnosis of cancer).
The mGPS and biochemical proportionality assumptions were
explored using log–log plots and were found to be satisfactory.
Kaplan–Meier estimator was used to analyse the relationship
between patient characteristics, mGPS, biological parameters,
tumour site and overall and cancer-specific survival (Tables
1B and 2B), as well as the relationship between mGPS and survival
(Figure 2A–F; Table 3). Cox proportional hazards model multi-
variate regression analysis (stratified by tumour site) was used to
determine the relationship between patient characteristics, the
mGPS and each biochemical parameter and survival (Tables 1C, D,
2C and D). w
2 (linear-by-linear) association was used to analyse the
relationship between the mGPS, patient characteristics and
biochemical parameters (Table 3). Owing to the number of
statistical comparisons a P-value of o0.01 was considered
significant. Analysis was performed using SPSS software (SPSS
Inc., Chicago, IL, USA).
RESULTS
From Glasgow Inflammation Outcome Study of 223303 patients
originally described (Proctor et al, 2010), 21669 patients were
identified as having a diagnosis of cancer in the Scottish Cancer
Registry and a blood sample taken between January 2000 and
December 2006. There were 9608 patients in this group who
had been sampled within 2 years before a diagnosis of cancer and
included in the present study. The majority, 7516 (78%), were
under 75 years of age. There were 5116 (53%) females and 4492
(47%) males. All patients had an identifiable postcode correspond-
ing to a SIMD 2006 score with 15% of cases being from affluent
areas (least deprived quintile of the Scottish population) and 38%
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sTable 1A The relationship between patient characteristics, mGPS,
biochemical parameters, tumour site and mortality in patients sampled
within 2 years before cancer diagnosis in the Glasgow Inflammation
Outcome Study
Patients
n¼9608
(%)
All
deaths
n¼6005
Cancer
deaths
n¼5122
Age
o65 years 4577 (48) 2258 2056
65–74 years 2936 (30) 2041 1729
X75 years 2095 (22) 1706 1337
Sex
Male 4492 (47) 3269 2794
Female 5116 (53) 2736 2328
SIMD 2006
1 (least deprived) 1419 (15) 722 616
2 1198 (13) 631 543
3 1445 (15) 850 739
4 1858 (19) 1222 1038
5 (most deprived) 3688 (38) 2580 2186
Tumour site
Breast 1956 (20) 452 328
Bladder 466 (5) 250 155
Gynaecological 533 (6) 298 256
Prostate 491 (5) 244 165
Gastroesophageal 869 (9) 772 719
Haematological 974 (10) 539 418
Renal 424 (5) 265 229
Colorectal 1065 (11) 673 571
Head and neck 501 (5) 316 220
Hepatopancreaticobiliary 605 (6) 563 536
Pulmonary 1724 (18) 1633 1525
Inflammation-based prognostic score
mGPS
0 3985 (42) 1647 1315
1 3204 (33) 2325 2039
2 2419 (25) 2033 1768
Biochemical parameter
C-reactive protein
p10mgl
 1 3985 (41) 1647 1315
410mgl
 1 5623 (59) 4358 3807
Albumin
435gl
 1 6907 (72) 3765 3183
o35gl
 1 2701 (28) 2240 1939
Adjusted calcium
o2.10mmoll
 1 329 (4) 229 177
2.10–2.60mmoll
 1 8856 (92) 5399 4601
42.60mmoll
 1 423 (4) 377 344
Bilirubin
o20mmoll
 1 7936 (83) 4693 3978
420mmoll
 1 1342 (14) 1071 942
Alkaline phosphatase
o80Ul
 1 177 (2) 56 48
80–280Ul
 1 6846 (71) 3704 3068
4280Ul
 1 2569 (27) 2236 1999
Aspartate transaminase
o40Ul
 1 7609 (18) 4439 3734
X40Ul
 1 1678 (79) 1340 1206
Alanine transaminase
o50Ul
 1 6350 (66) 3588 3036
X50Ul
 1 992 (10) 741 677
g-Glutamyl transferase
Mo70Ul
 1;F o40Ul
 1 6082 (63) 3336 2765
MX70Ul
 1;F X40Ul
 1 3264 (34) 2488 2212
Abbreviations: SIMD¼Scottish Index of Multiple Deprivation; mGPS¼modified
Glasgow Prognostic Score.
Table 1B The relationship between patient characteristics, mGPS,
biochemical parameters, tumour site and survival in patients sampled within
2 years before cancer diagnosis in the Glasgow Inflammation Outcome Study
n¼9608
5-year
overall
survival
% P-value
5-year
cancer-
specific
survival % P-value
Age
p65 years 50 54
65–74 years 30 38
X75 years 19 o0.001 30 o0.001
Sex
Male 27 34
Female 47 o0.001 53 o0.001
SIMD
1 (least deprived) 50 55
24 7 5 2
34 1 4 6
43 4 4 1
5 (most deprived) 30 o0.001 37 o0.001
Tumour site
Breast 77 83
Bladder 57 64
Gynaecological 44 52
Prostate 50 64
Gastroesophageal 11 13
Haematological 46 54
Renal 39 38
Colorectal 37 43
Head and neck 34 50
Hepatopancreaticobiliary 6 7
Pulmonary 5 o0.001 7 o0.001
Inflammation-based prognostic
score
mGPS
05 9 6 5
12 8 3 4
21 5 o0.001 21 o0.001
Biochemical parameter
C-reactive protein
p10mgl
 1 59 65
410mgl
 1 23 o0.001 28 o0.001
Albumin
X35gl
 1 46 52
o35gl
 1 16 o0.001 22 o0.001
Adjusted calcium
o2.10mmoll
 1 30 41
2.10–2.60mmoll
 1 39 45
42.60mmoll
 1 10 o0.001 14 o0.001
Bilirubin
o20mmoll
 1 41 47
X20mmoll
 1 20 o0.001 25 o0.001
Alkaline phosphatase
o80Ul
 1 62 66
80–280Ul
 1 46 53
4280Ul
 1 13 o0.001 17 o0.001
Aspartate transaminase
o40Ul
 1 42 48
X40Ul
 1 20 o0.001 24 o0.001
Alanine transaminase
o50Ul
 1 43 50
X50Ul
 1 25 o0.001 28 o0.001
g-Glutamyl transferase
Mo70Ul
 1;F o40Ul
 1 45 52
MX70Ul
 1;F X40Ul
 1 23 o0.001 28 o0.001
Abbreviations: SIMD¼Scottish Index of Multiple Deprivation; mGPS¼modified
Glasgow Prognostic Score.
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population). The minimum follow-up was 29 months and the
maximum was 112 months (median 61 months for survivors).
The relationship between patient characteristics, mGPS, bio-
chemical parameters, tumour site and mortality in patients with
Table 1C The relationship between the mGPS, biochemical parameters
and survival in patients sampled within 2 years before cancer diagnosis in
the Glasgow Inflammation Outcome Study
Overall survival Cancer-specific survival
HR P-value HR P-value
mGPS
01 o0.001 1 o0.001
1 1.79 o0.001 1.92 o0.001
2 2.87 o0.001 3.01 o0.001
Adjusted calcium
o2.10mmoll
 1 1.25 0.001 1.15 0.070
2.10–2.60mmoll
 1 1 o0.001 1 o0.001
42.60mmoll
 1 2.30 o0.001 2.38 o0.001
Bilirubin
o20mmoll
 1 1 o0.001 1 o0.001
X20mmoll
 1 1.53 o0.001 1.55 o0.001
Alkaline phosphatase
o80Ul
 1 0.71 0.012 0.74 0.037
80–280Ul
 1 1 o0.001 1 o0.001
4280Ul
 1 2.12 o0.001 2.19 o0.001
Aspartate transaminase
o40Ul
 1 1 o0.001 1 o0.001
X40Ul
 1 1.66 o0.001 1.73 o0.001
Alanine transaminase
o50Ul
 1 1 o0.001 1 o0.001
X50Ul
 1 1.36 o0.001 1.39 o0.001
g-Glutamyl transferase
Mo70Ul
 1;F o40Ul
 1 1 o0.001 1 o0.001
MX70Ul
 1;F X40Ul
 1 1.85 o0.001 1.85 o0.001
Abbreviations: HR¼hazard ratio; mGPS¼modified Glasgow Prognostic Score.
Adjusted for age, sex, deprivation and stratified by tumour site.
Table 1D The relationship between patient characteristics, mGPS and
survival in patients sampled within 2 years before cancer diagnosis in the
Glasgow Inflammation Outcome Study
Overall survival Cancer-specific survival
n¼9608 HR 95 % CI P-value HR 95 % CI P-value
Age
p65 years 1 o0.001 1 o0.001
65–74 years 1.35 1.26–1.43 o0.001 1.20 1.13–1.29 o0.001
X75 years 1.93 1.80–2.06 o0.001 1.59 1.48–1.70 o0.001
Sex
Male 1 0.037 1 0.132
Female 0.94 0.037 0.95 0.132
SIMD
1 (least deprived) 1 o0.001 1 0.003
2 1.02 0.684 1.02 0.773
3 1.09 0.090 1.09 0.136
4 1.16 1.06–1.27 0.002 1.12 0.025
5 (most deprived) 1.22 1.12–1.33 o0.001 1.17 1.06–1.28 0.001
mGPS
01 o0.001 1 o0.001
1 1.79 1.68–1.91 o0.001 1.92 1.79–2.06 o0.001
2 2.87 2.68–3.08 o0.001 3.01 2.79–3.24 o0.001
Abbreviations: HR¼hazard ratio; CI¼confidence interval; SIMD¼Scottish Index of
Multiple Deprivation; mGPS¼modified Glasgow Prognostic Score. Multivariate
analysis stratified by tumour site.
Table 2A The relationship between patient characteristics, mGPS,
biochemical parameters, tumour site and mortality in patients sampled
within 2 months before cancer diagnosis in the Glasgow Inflammation
Outcome Study
Patients
n¼5397
(%)
All
deaths
n¼3405
Cancer
deaths
n¼2993
Age
p65 years 2452 (46) 1192 1093
65–74 years 1686 (31) 1172 1035
X75 years 1259 (23) 1041 865
Sex
Male 2315 (43) 1829 1620
Female 3082 (57) 1576 1373
SIMD 2006
1 (least deprived) 802 (15) 392 335
2 685 (13) 344 304
3 766 (14) 429 388
4 974 (18) 648 572
5 (most deprived) 2170 (40) 1592 1394
Tumour site
Breast 1383 (26) 235 166
Bladder 181 (3) 97 60
Gynaecological 188 (3) 129 108
Prostate 159 (3) 106 75
Gastroesophageal 456 (8) 400 371
Haematological 427 (8) 255 211
Renal 179 (3) 117 107
Colorectal 569 (11) 363 309
Head and neck 191 (4) 130 94
Hepatopancreaticobiliary 486 (9) 455 438
Pulmonary 1178 (22) 1118 1054
Inflammation-based prognostic score
mGPS
0 2243 (41) 890 743
1 1815 (34) 1385 1252
2 1339 (25) 1130 998
Biochemical parameter
Adjusted calcium
o2.10mmoll
 1 165 (3) 116 91
2.10–2.60mmoll
 1 4971 (92) 3058 2685
42.60mmoll
 1 261 (5) 231 217
Bilirubin
o20mmoll
 1 4366 (81) 2558 2230
X20mmoll
 1 855 (16) 720 655
Alkaline phosphatase
o80Ul
 1 98 (2) 28 25
80–280Ul
 1 3788 (70) 2039 1746
4280Ul
 1 1502 (30) 1333 1217
Aspartate transaminase
o40Ul
 1 4191 (78) 2409 2084
X40Ul
 1 1034 (19) 876 812
Alanine transaminase
o50Ul
 1 3740 (69) 2127 1847
X50Ul
 1 636 (12) 514 483
g-Glutamyl transferase
Mo70Ul
 1;F o40Ul
 1 3393 (63) 1841 1581
MX70Ul
 1;F X40Ul
 1 1867 (35) 1472 1338
Abbreviations: SIMD¼Scottish Index of Multiple Deprivation; mGPS¼modified
Glasgow Prognostic Score.
Glasgow Inflammation Outcome Study
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the Glasgow Inflammation Outcome Study is shown in Table 1A.
In total, 9608 patients were studied. On follow up, there were 6005
Table 2B The relationship between patient characteristics, mGPS,
biochemical parameters, tumour site and survival in patients sampled within
2 months before cancer diagnosis in the Glasgow Inflammation Outcome
Study
n¼5397
5-year
overall
survival
% P-value
5-year
cancer-
specific
survival % P-value
Age
p65 years 51 54
65–74 years 30 35
X75 years 18 o0.001 26 o0.001
Sex
Male 21 26
Female 49 o0.001 54 o0.001
SIMD
1 (least deprived) 52 57
25 0 5 4
34 3 4 7
43 2 3 8
5 (most deprived) 27 o0.001 32 o0.001
Tumour site
Breast 83 87
Bladder 48 63
Gynaecological 33 39
Prostate 32 46
Gastroesophageal 12 15
Haematological 40 47
Renal 35 39
Colorectal 37 43
Head and neck 29 43
Hepatopancreaticobiliary 5 6
Pulmonary 5 o0.001 7 o0.001
Inflammation-based prognostic score
mGPS
06 0 6 5
12 4 2 9
21 5 o0.001 20 o0.001
Biochemical parameter
Adjusted calcium
o2.10mmoll
 1 29 39
2.10–2.60mmoll
 1 38 43
42.60mmoll
 1 10 o0.001 13 o0.001
Bilirubin
o20mmoll
 1 41 47
X20mmoll
 1 15 o0.001 19 o0.001
Alkaline phosphatase
o80Ul
 1 68 69
80–280Ul
 1 46 52
4280Ul
 1 11 o0.001 14 o0.001
Aspartate transaminase
o40Ul
 1 42 48
X40Ul
 1 15 o0.001 18 o0.001
Alanine transaminase
o50Ul
 1 43 48
X50Ul
 1 19 o0.001 21 o0.001
g-Glutamyl transferase
Mo70Ul
 1;F o40Ul
 1 46 51
MX70Ul
 1;F X40Ul
 1 20 o0.001 25 o0.001
Abbreviations: SIMD¼Scottish Index of Multiple Deprivation; mGPS¼modified
Glasgow Prognostic Score.
Table 2C The relationship between the mGPS, biochemical parameters
and survival in patients sampled within 2 months before cancer diagnosis in
the Glasgow Inflammation Outcome Study
Overall survival Cancer-specific survival
HR P-value HR P-value
mGPS
01 o0.001 1 o0.001
1 1.67 o0.001 1.74 o0.001
2 2.36 o0.001 2.40 o0.001
Adjusted calcium
o2.10mmoll
 1 1.17 0.107 1.07 0.530
2.10–2.60mmoll
 1 1 o0.001 1 o0.001
42.60mmoll
 1 1.96 o0.001 2.04 o0.001
Bilirubin
o20mmoll
 1 1 o0.001 1 o0.001
X20mmoll
 1 1.49 o0.001 1.49 o0.001
Alkaline phosphatase
o80Ul
 1 0.78 0.016 0.68 0.053
80–280Ul
 1 1 o0.001 1 o0.001
4280Ul
 1 1.93 o0.001 1.96 o0.001
Aspartate transaminase
o40Ul
 1 1 o0.001 1 o0.001
X40Ul
 1 1.66 o0.001 1.71 o0.001
Alanine transaminase
o50Ul
 1 1 o0.001 1 o0.001
X50Ul
 1 1.34 o0.001 1.37 o0.001
g-Glutamyl transferase
Mo70Ul
 1;F o40Ul
 1 1 o0.001 1 o0.001
MX70Ul
 1;F X40Ul
 1 1.79 o0.001 1.79 o0.001
Abbreviations: HR¼hazard ratio; mGPS¼modified Glasgow Prognostic Score.
Adjusted for age, sex, deprivation and stratified by tumour site.
Table 2D The relationship between patient characteristics, mGPS and
survival in patients sampled within 2 months before cancer diagnosis in the
Glasgow Inflammation Outcome Study
Overall survival
Cancer-specific
survival
n¼5397 HR 95 % CI P-value HR 95 % CI P-value
Age
p65 years 1 o0.001 1 o0.001
65–74 years 1.31 1.20–1.42 o0.001 1.22 1.12–1.33 o0.001
X75 years 1.92 1.76–2.10 o0.001 1.70 1.55–1.87 o0.001
Sex
Male 1 0.340 1 0.507
Female 0.96 0.340 0.97 0.507
SIMD
1 (least deprived) 1 o0.001 1 o0.001
2 1.05 0.503 1.08 0.364
3 1.07 0.342 1.11 0.179
4 1.20 1.06–1.36 0.005 1.20 1.05–1.38 0.008
5 (most deprived) 1.30 1.16–1.45 o0.001 1.28 1.14–1.45 o0.001
mGPS
01 o0.001 1 o0.001
1 1.67 1.53–1.83 o0.001 1.74 1.59–1.91 o0.001
2 2.36 2.15–2.59 o0.001 2.40 2.17–2.65 o0.001
Abbreviations: HR¼hazard ratio; CI¼confidence interval; SIMD¼Scottish Index of
Multiple Deprivation; mGPS¼modified Glasgow Prognostic Score. Multivariate
analysis stratified by tumour site.
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s(63%) deaths of which 5122 (53%) were cancer deaths. The median
time from blood sampling to diagnosis was 1.4 months.
The relationship between patient characteristics, mGPS,
biochemical parameters, tumour site and survival in patients with
blood samples taken within 2 years before a diagnosis of cancer in
the Glasgow Inflammation Outcome Study is shown in Table 1B
and Figure 1. Increasing age, male gender and increasing
deprivation were associated with reduced 5-year overall and
cancer-specific survival (all Po0.001). A low albumin, an elevated
mGPS, C-reactive protein, adjusted calcium, bilirubin, Alk phos,
AST, ALT and GGT were associated with a reduced 5-year overall
and cancer-specific survival (all Po0.001).
In the present cohort, the majority of patients with a low albumin
concentration (n¼2701) also had an elevated C-reactive protein
concentration (n¼2419, 90%). Few patients had a low albumin but a
C-reactive protein concentration in the normal range (n¼282).
A low-albumin concentration alone was not significantly associated
with cancer-specific survival in bladder (P¼0.913), gynaecological
(P¼0.737), prostate (P¼0.500), gastroesophageal (P¼0.893), renal
(P¼0.945), colorectal (P¼0.133), head and neck (P¼0.740) and
hepatopancreaticobiliary (P¼0.209) cancers. In Cox multivariate
regression analysis, the relationship between a mGPS of 2 and
cancer-specific survival (hazard ratio (HR): 3.01, Po0.001) was
stronger than that between C-reactive protein alone and cancer-
specific survival (HR: 2.29, Po0.001). Therefore, in the remaining
tables and figures only the mGPS was considered.
The relationship between the mGPS and cancer-specific survival
in breast (n¼1956), bladder (n¼466), gynaecological (n¼533),
prostate (n¼491), gastroesophageal (n¼869), haematological
(n¼974), renal (n¼424), colorectal (n¼1065), head and neck
(n¼501), hepatopancreaticobiliary (n¼605) and pulmonary
(n¼1724) cancers is shown in Figure 2A–K, respectively.
The relationship between the mGPS, biochemical parameters
and survival in patients sampled within 2 years before cancer
diagnosis in the Glasgow Inflammation Outcome Study, stratified
by tumour site, is shown in Table 1C. On survival analysis, a raised
mGPS, adjusted calcium, bilirubin, Alk phos, AST, ALT and GGT
were all associated with increased overall and cancer-specific
mortality independent of age, sex and deprivation (all Po0.001).
The relationship between patient characteristics, mGPS and
survival in patients sampled within 2 years before cancer diagnosis
in the Glasgow Inflammation Outcome Study is shown in Table 1D.
On multivariate survival analysis, stratified by tumour site,
increasing age and mGPS were associated with increased overall
and cancer-specific mortality (all Po0.001). Patients in the most
deprived quintile (5) had a reduced overall and cancer-specific
survival (both Po0.01), but a significant linear relationship across
deprivation categories was not observed.
The relationship between patient characteristics, mGPS,
biochemical parameters, tumour site and mortality in patients
with blood samples taken within 2 months before a diagnosis of
cancer in the Glasgow Inflammation Outcome Study is shown in
Table 2A. In total, 5397 patients were studied. On follow up, there
were 3405 (63%) deaths, of which 2993 (56%) were cancer deaths.
The median time from blood sampling to diagnosis was 0.4 month.
The relationship between patient characteristics, mGPS,
biochemical parameters, tumour site and survival in patients with
blood samples taken within 2 months before a diagnosis of cancer
in the Glasgow Inflammation Outcome Study is shown in Table 2B.
Increasing age, male gender and increasing deprivation were
associated with reduced 5-year overall and cancer-specific survival
(all Po0.001). An elevated mGPS, adjusted calcium, bilirubin, Alk
phos, AST, ALT and GGT were associated with a reduced 5-year
overall and cancer-specific survival (all Po0.001).
The relationship between the mGPS, biochemical parameters
and survival in patients sampled within 2 months before cancer
diagnosis in the Glasgow Inflammation Outcome Study, stratified
by tumour site, is shown in Table 2C. On survival analysis, a raised
mGPS, adjusted calcium, bilirubin, Alk phos, AST, ALT and GGT
were all associated with increased overall and cancer-specific
mortality independent of age, sex and deprivation (all Po0.001).
The relationship between patient characteristics, mGPS and
survival in patients sampled within 2 months before cancer
diagnosis in the Glasgow Inflammation Outcome Study is shown in
Table 2D. On multivariate survival analysis, stratified by tumour
site, increasing age and mGPS were associated with increased
overall and cancer-specific mortality (all Po0.001). Patients in the
most deprived quintiles (4 and 5) had a reduced overall and
cancer-specific survival (both Po0.01), but a significant linear
relationship across deprivation categories was not observed.
In the present cohort of patients sampled within 2 months prior
to cancer diagnosis, only a limited number of patients had staging
information available from the Scottish Cancer Registry. Tumour
staging was available in 533 (39%) patients with breast cancer, 430
(76%) patients with colorectal cancer and 158 (13%) patients with
pulmonary cancer. All other cancer groups had no staging
available. Therefore, only in colorectal cancer was staging available
in over 50% of patients. In these colorectal cancer patients, there
were 30 Dukes A, 113 Dukes B, 131 Dukes C and 156 Dukes D, and
236 died of their cancer. When Dukes stage was included in the
multivariate analysis, both Dukes stage (HR: 3.59, 95% confidence
interval (CI): 2.95–4.39, Po0.001) and mGPS (HR: 1.49, 95% CI:
1.26–1.76, Po0.001) remained independently associated with
survival.
The relationship between the mGPS, patient characteristics,
biochemical parameters and overall and cancer-specific survival in
patients with blood samples taken within 2 years before a diagnosis
of cancer in the Glasgow Inflammation Outcome Study is shown in
Table 3. An increasing mGPS was associated with increasing age,
male gender, increasing adjusted calcium, bilirubin, Alk phos,
AST, ALT and GGT (all Po0.001). An increasing mGPS was
associated with a reduction in overall and cancer-specific survival
(both Po0.001).
DISCUSSION
Previously, in large cohort studies, a number of biochemical
parameters (other than C-reactive protein and albumin that
compose the mGPS) including bilirubin (Temme et al, 2001),
Alk phos (Tonelli et al, 2009), GGT (Kazemi-Shirazi et al, 2007)
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Figure 1 The relationship between tumour site and cancer-specific
5-year survival. Tumours from top to bottom: breast, gynaecological,
bladder, prostate, haematological, head and neck, colorectal, renal,
gastroesophageal, pulmonary and hepatopancreaticobiliary.
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Figure 2 (A–K) The relationship between the mGPS 0 (top, small dash line), mGPS 1 (middle, large dash line) and mGPS 2 (bottom, solid line) and
cancer specific survival (Po0.001) in each tumour site.
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sand calcium (Leifsson and Ahren, 1996), have been reported to
predict overall and cancer-specific survival.
In the present study, the mGPS and the above biochemical
parameters were shown to have prognostic value in all patients
with a likely ongoing malignant process as well as those at the time
of diagnosis. Moreover, an mGPS of 2 was associated with an
B160% reduction in both overall and cancer-specific survival
independent of tumour site. In contrast, an increase in adjusted
calcium was associated with an approximate 130% reduction in
both overall and cancer specific survival; an increase in bilirubin
was associated with an approximate 50% reduction in both overall
and cancer specific survival; an increase in Alk phos was
associated with an approximate 110% reduction in both overall
and cancer specific survival: an increase in AST was associated
with an approximate 70% reduction in both overall and cancer
specific survival; an increase in ALT was associated with an
approximate 40% reduction in both overall and cancer specific
survival and an increase in GGT was associated with an
approximate 80% reduction in both overall and cancer specific
survival. These results indicate that the mGPS and the biochemical
parameters measured have prognostic significance in the tumour
sites studied. Moreover, the results show that a raised mGPS is
most closely associated with a reduction in both overall
and cancer-specific survival, independent of tumour site.
The GPS was originally developed, from the combination of
C-reactive protein and albumin, in a cohort of patients with
advanced non-small cell lung cancer (Forrest et al, 2004). In this
study, they were combined to give a score of 0 for both a normal
C-reactive protein and albumin, 1 for either an abnormal
C-reactive protein alone or albumin alone and 2 for both an
abnormal C-reactive protein and albumin. It was clear from this
analysis that a low albumin alone was uncommon, accounting for
o10% of all observations, and raised the possibility that this was
not associated with a reduced survival. When examined in a cohort
of patients undergoing potentially curable resection for colorectal
cancer (McMillan et al, 2008) the results showed that the
relationship between an abnormal albumin alone and cancer-
specific survival was similar to that of a normal albumin.
Therefore, the GPS was modified (mGPS) to give a score of
1 only for an elevated C-reactive protein concentration. In the
present study, in a much larger cohort, a low albumin alone was
associated with poor survival in some tumours (breast, haemato-
logical and pulmonary) but not others (bladder, gynaecological,
prostate, gastroesophageal, renal, colorectal, head and neck and
hepatopancreaticobiliary). Therefore, the present results would
indicate the greater consistency of the mGPS and suggest its
general use rather than that of the GPS.
In the present study, we examined the relationship between the
mGPS, biochemical parameters and survival in all patients with
cancer as well as a subgroup of patients who were sampled within
2 months before a diagnosis of cancer. This was carried out with the
premise that patients sampled within 2 years would have a mGPS
associated with an ongoing malignant process and those sampled
within 2 months would have a mGPS associated with their cancer
diagnosis. With reference to the mGPS, the hazard ratios associated
with survival remained consistent in both analyses and confirms the
temporal utility of this inflammation-based prognostic score.
To date the mGPS has been shown to have prognostic value,
independent of TNM stage, in lung, gastrointestinal and renal
cancers (McMillan, 2008, 2009). In the present study, there was
insufficient staging information available on all cancer groups, apart
from colorectal, to demonstrate that the mGPS is universally
prognostic independent of stage. However, the results of the present
and previous studies (McMillan, 2009; Roxburgh and McMillan,
2010) would suggest that the mGPS might also have independent
prognostic in other cancer types. Further detailed studies, including
tumour stage, in breast, bladder, gynaecological, prostate, haemato-
logical, head and neck and hepatopancreaticobiliary cancers are
required to confirm this hypothesis. Nevertheless, if this were to
prove to be the case, then similar to the TNM staging system, the
mGPS may be implemented universally in the assessment of cancer
patients. Moreover, that they (TNM stage and mGPS) may be
combined in a single staging system, which would not only account
for tumour stage but also the host systemic inflammatory response.
The present cohort study has a number of limitations.
The patients were selected on the basis that measurements of
C-reactive protein, albumin and calcium had been performed and
were therefore not necessarily representative of all cancer patients
diagnosed and treated in the North Glasgow area. It is also
recognised that patients with cancer may have concurrent
Table 3 The relationship between the mGPS, patient characteristics,
biochemical parameters and survival in patients sampled within 2 years
before cancer diagnosis in the Glasgow Inflammation Outcome Study
mGPS
0 n (%) 1 n (%) 2 n (%) P-value
Age
p65 years 2193 (55) 1464 (46) 920 (38)
65–74 years 1091 (27) 1007 (31) 838 (35)
X75 years 701 (18) 733 (23) 661 (27) o0.001
Sex
Male 1516 (38) 1672 (52) 1304 (54)
Female 2469 (62) 1532 (48) 1115 (46) o0.001
SIMD 2006
1 (least deprived) 739 (19) 383 (12) 297 (12)
2 592 (15) 342 (11) 264 (11)
3 633 (16) 460 (14) 352 (15)
4 727 (18) 613 (19) 518 (21)
5 (most deprived) 1294 (32) 1406 (44) 988 (41) o0.001
Adjusted calcium
o2.10mmoll
 1 76 (2) 87 (3) 166 (7)
2.10–2.60mmoll
 1 3835 (96) 2972 (93) 2049 (85)
42.60mmoll
 1 74 (2) 145 (4) 204 (8) o0.001
Bilirubin
o20mmoll
 1 3564 (92) 2621 (85) 1751 (76)
X20mmoll
 1 324 (8) 466 (15) 552 (24) o0.001
Alkaline phosphatase
o80Ul
 1 93 (2) 16 (0) 68 (3)
80–280Ul
 1 3428 (86) 2163 (68) 1255 (52)
4280Ul
 1 457 (12) 1020 (32) 1092 (45) o0.001
Aspartate transaminase
o40Ul
 1 3491 (90) 2501 (81) 1617 (70)
X40Ul
 1 399 (10) 593 (19) 686 (30) o0.001
Alanine transaminase
o50Ul
 1 3016 (91) 1982 (85) 1352 (79)
X50Ul
 1 301 (9) 337 (15) 354 (21) o0.001
g-Glutamyl transferase
Mo70Ul
 1;
Fo40Ul
 1
3071 (79) 1875 (60) 1136 (49)
MX70Ul
 1;
FX40Ul
 1
839 (21) 1242 (40) 1183 (51) o0.001
Overall survival in
months (mean, CI)
70 (68–72) 37 (36–39) 22 (21–24) o0.001
Cancer-specific survival in
months (mean, CI)
77 (75–79) 43 (41–45) 27 (26–29) o0.001
Abbreviations: CI¼confidence interval; SIMD¼Scottish Index of Multiple
Deprivation; mGPS¼modified Glasgow Prognostic Score.
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smorbidity causing a rise in their C-reactive protein and derange-
ment of their albumin and other biochemical parameters.
In summary, the results of the present study indicate
that, in a large patient cohort, the systemic inflammatory response,
as evidenced by the mGPS, is common and that the mGPS is
a powerful prognostic factor compared with other bio-
chemical parameters, independent of tumour site in patients with
cancer.
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